Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...

The trial will include patients with pancreatic, colorectal, non-small cell lung, and other cancers that harbor KRAS G12V mutations.

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in ...

REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...